FDA expands Sanofi’s Tzield use to children as young as 1 for type 1 diabetes delay (SNY:NASDAQ)
Summary
FDA approves Sanofi’s Tzield for ages 1+ to delay type 1 diabetes onset in stage 2 patients.
Description
FDA approves Sanofi’s Tzield for ages 1+ to delay type 1 diabetes onset in stage 2 patients.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source